High dose vitamin C injections have shown positive results in fighting cancer cells in studies done in vitro, on mice and on humans. Peer-reviewed medical research has been recently published in the journal Science Translational Medicine that reports the findings of a team of researchers from the University of Kansas who tested the effects of vitamin C given in high doses intravenously on a group of human subjects with cancer. They found that the injections fought cancer cells yet left healthy cells well intact unlike chemotherapy.
The BBC reports that vitamin C effectively targeted ovarian cancer cells while completely avoiding healthy cells. The benefits of high-dose vitamin C injections were also observed in conjunction with chemotherapy. Some are suggesting that the injections provide a great boost alongside chemo treatment. However chemo does destroy all cells, both healthy and not and is often the cause of death for cancer patients.
Research on high dose vitamin C injections began in the 1970s when Linus Pauling, a chemist from Oregon State University began his research. New research involved injecting high doses of vitamin C intravenously into human ovarian cells. The tests were conducted in vitro, on mice and in 22 humans subjects.
“Patients are looking for safe and low-cost choices in their management of cancer… Intravenous vitamin C has that potential based on our basic science research and early clinical data.” Dr. Jeanne Drisko, a co-author of the study.
Researchers admit more research is unlikely because drug companies cannot patent vitamins.
Generally the next step in this type of research would be creating human clinical trials that are much larger. Regardless of the fact this study is quite convincing, larger and more widespread testing would need to be done. But these types of trials cost a great deal of money. While clinical trials are often funded by large drug companies when testing out new medications, the researchers involved in this study feel drug companies won’t fund such research because they can’t patent the natural substance that is vitamin C. Allowing research like this could potentially destroy the multi-billion dollar cancer industry.
“Because vitamin C has no patent potential, its development will not be supported by pharmaceutical companies… We believe that the time has arrived for research agencies to vigorously support thoughtful and meticulous clinical trials with intravenous vitamin C.” Qi Chen, lead author of the new study.
Conventional medicine has a hard time accepting studies like this as they would have a lot of questions to answer should they admit the validity of this research. They would have to explain why this type of knowledge has been known for decades and yet low percentage, barbaric and expensive methods like radiation and chemotherapy remain the number one method in treating cancer. This would also come with a huge loss in profit due to the fact that most proven and effective cancer treatments like this and cannabis oil are very cheap to produce.
“[A]scorbate is processed by the body in different ways when administered orally versus intravenously… Oral doses [of vitamin C] act as antioxidants, protecting cells from damage caused by reactive compounds that contain oxygen. But vitamin C given intravenously can have the opposite effect by promoting the formation of one of those compounds: hydrogen peroxide. Cancer cells are particularly susceptible to damage by such reactive oxygen-containing compounds.” Heidi Ledford for Nature.
Provided by Joe Martino